Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArdelyxMEX:ARDX 69 Forward PE Ratio is 414.15 as of Jul. 29, 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 69/100 and a GF Value™ of MXN202.67 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 354 Biotechnology companies, Ardelyx ranks worse than 95.2% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Ardelyx Forward PE Ratio Related Terms
Ardelyx Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Ardelyx's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx Forward PE Ratio Chart
Ardelyx Annual Data
Trend
2025-12
Forward PE Ratio
42.83
Ardelyx Quarterly Data
2025-09
2025-12
2026-03
Forward PE Ratio
106.82
42.83
2,740.43
MEX:ARDX vs IMTX, TRAX, AVLN: Forward PE Ratio Comparison
For the Biotechnology subindustry, Ardelyx's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Ardelyx's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Ardelyx (MEX:ARDX) has a Forward PE Ratio of 414.15 as of Jul. 29, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #337 out of 354 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Ardelyx's Forward PE Ratio too high?
Ardelyx's current Forward PE Ratio is 414.15. The Biotechnology industry median Forward PE Ratio is 22.35. Ardelyx's value of 414.15 is 1753% above this industry median. Based on the distribution chart, Ardelyx ranks #337 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Forward PE Ratio compare to IMTX and TRAX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #337 out of 354 companies for Forward PE Ratio. This places Ardelyx in the lower half of its industry. The industry median Forward PE Ratio is 22.35. Ardelyx's value of 414.15 is 1753% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.35, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ardelyx's current Forward PE Ratio of 414.15 is 1753% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ardelyx and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ardelyx's current Forward PE Ratio is 414.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (MEX:ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN202.67, compared to a current price of MXN99.00 — trading 51.2% below its estimated fair value. The current Forward PE Ratio is 414.15 and 1753% above the Biotechnology industry median of 22.35. Ardelyx's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current Forward PE Ratio is 414.15 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (MEX:ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of MXN99.00 is trading 51.2% below its estimated GF Value™ of MXN202.67.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for MEX:ARDX:
Forward PE Ratio: 414.15
GF Value™: MXN202.67 vs. price of MXN99.00 (51.2% below fair value)
Industry Position: 1753% above the Biotechnology median (#337 of 354)
No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score
Get the complete analysis for MEX:ARDX
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARDX has been successfully added to your 
